Immunodeficiency Virus (e.g., Hiv, Etc.) Patents (Class 424/208.1)
  • Publication number: 20130004529
    Abstract: Improved anti-HIV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus sequences for HIV Subtype A Envelope protein, those having consensus sequences for HIV Subtype B Envelope protein, those having consensus sequences for HIV Subtype C Envelope protein, those having consensus sequences for HIV Subtype D Envelope protein, those having consensus sequences for HIV Subtype B consensus Nef-Rev protein, and those having consensus sequences form HIV Gag protein subtypes A, B, C and D. Improved anti-HPV immunogens and nucleic acid molecules that encode them; improved anti-HCV immunogens and nucleic acid molecules that encode them; improved hTERT immunogens and nucleic acid molecules that encode them; and improved anti-Influenza immunogens and nucleic acid molecules that encode them are disclosed as well methods of inducing an immune response in an individual against HIV, HPV, HCV, hTERT and Influenza are disclosed.
    Type: Application
    Filed: April 27, 2012
    Publication date: January 3, 2013
    Inventors: David B. Weiner, Jian Yan, Dominick Laddy
  • Publication number: 20130004538
    Abstract: This document relates to compositions and methods for modulating an immune response. For example, compositions of immunostimulatory CpG oligonucleotides derived from retroviral genomes are provided.
    Type: Application
    Filed: July 9, 2012
    Publication date: January 3, 2013
    Inventors: Lee A. Bulla, JR., Jeffrey Marcus Clark, Natalya Griko, Jian Sun, Ralph Clark
  • Publication number: 20120328627
    Abstract: The present invention relates to a compound represented by formula (I): wherein all symbols are as defined here, a salt thereof, a solvate thereof, or a prodrug thereof. The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, rejection of transplanted organ, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.
    Type: Application
    Filed: August 28, 2012
    Publication date: December 27, 2012
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Masaya KOKUBO, Motoyuki Tanaka, Hiroshi Ochiai, Yoshikazu Takaoka, Shiro Shibayama
  • Publication number: 20120328641
    Abstract: Stabilized forms of gp120 polypeptide, nucleic acids encoding these stabilized forms, vectors comprising these nucleic acids, and methods of using these polypeptides, nucleic acids, vectors and host cells are disclosed. Crystal structures and computer systems including atomic coordinates for stabilized forms of gp120, and gp120 with an extended V3 loop, and methods of using these structures and computer systems are also disclosed.
    Type: Application
    Filed: August 14, 2012
    Publication date: December 27, 2012
    Inventors: Peter Kwong, John Mascola, Gary Nabel, Richard Wyatt, Barna Dey, Ling Xu, Tongqing Zhou, Joseph Sodroski, Wen Yuan, Shi-Hua Xiang
  • Patent number: 8338089
    Abstract: The present invention relates, e.g., to a method for inhibiting infectivity of a lentivirus (e.g., a lentivirus which expresses a Viral infectivity factor (Vif) protein), such as, e.g., SIV, SHIV and/or HIV, comprising contacting a cell which is producing the virus with an antiviral-effective amount of a membrane-permeable Zinc (Zn) chelator, wherein the antiviral-effective amount of the Zn chelator does not substantially inhibit proteins in the cell which contain Zn-binding motifs other than lentivirus Vif. Kits and pharmaceutical compositions are also disclosed, as is a method for identifying inhibitors of lentiviruses that target a specific zinc-binding motif of the lentivirus Vif protein.
    Type: Grant
    Filed: November 20, 2007
    Date of Patent: December 25, 2012
    Assignee: The Johns Hopkins University
    Inventors: Xiao-Fang Yu, Elana S. Erhlich, Xiao Zuoxiang
  • Patent number: 8338582
    Abstract: The present invention refers to new epitopes recognized by CD4+ T-lymphocytes. In addition, the present invention refers to the uses of such epitopes and their combinations, particularly in the treatment or prevention of disorders caused by the HIV-1 virus. The present invention also refers to a composition comprising said epitopes and the uses of said composition, particularly in the treatment or prevention of disorders caused by the HIV-1 virus. The present invention also refers to anti-HIV-1 prophylactic vaccines and therapeutic vaccines. Furthermore, the present invention refers to a method for the identification of epitopes and methods for treating or preventing an infection caused by the HIV-1 virus.
    Type: Grant
    Filed: March 5, 2008
    Date of Patent: December 25, 2012
    Assignees: Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Fundacao Zerbini, Universidade de Sao Paulo-USP
    Inventors: Edecio Cunha Neto, Jorge Elias Kalil Filho, Simone Goncalves Da Fonseca
  • Publication number: 20120321699
    Abstract: The present invention relates, in general, to an immunogen for HIV vaccination and, in particular, to a method of inducing the production of protective anti-HIV antibodies by targeting B cell germline and clone intermediates using a combination of HIV envelope and non-HIV immunogens. The invention also relates to compositions suitable for use in such a method.
    Type: Application
    Filed: February 25, 2011
    Publication date: December 20, 2012
    Inventors: Barton F. Haynes, Hua-Xin Liao, Georgia Tomaras, Thomas B. Kepler, Kwan-Ki Hwang, S.Munir Alam, Yang Liu, T. Matt Holl, Guang Yang, Garnett Kelsoe, Mattia Bonsignori
  • Patent number: 8333980
    Abstract: The invention provides methods of modulating an immune response to a second antigen which entail administration of a first antigen and an immunostimulatory polynucleotide. Modulation of the immune response is generally manifested as stimulation of a Th1 response.
    Type: Grant
    Filed: November 13, 2008
    Date of Patent: December 18, 2012
    Assignee: Dynavax Technologies Corporation
    Inventors: Gary Van Nest, Stephen F. Tuck, Joseph Eiden, Jr.
  • Publication number: 20120315296
    Abstract: The present invention relates to the design of gene transfer vectors and especially provides lentiviral gene transfer vectors suitable for either a unique administration or for iterative administration in a host, and to their medicinal application (such as vaccination against Immunodeficiency Virus, especially suitable in human hosts). Gene transfer vectors can be either integrative or non-integrative vectors. The invention encompasses prophylactic, therapeutic, symptomatic, and curative treatments of animals, including humans, as well as gene therapy and vaccination in vivo.
    Type: Application
    Filed: April 23, 2012
    Publication date: December 13, 2012
    Inventors: Pierre Charneau, Anne-Sophie Beignon, Frederic Philippe Coutant, Karine Courbeyrette
  • Publication number: 20120308593
    Abstract: The disclosure relates to immunological compositions for vaccinating human beings against infection by the Human Immunodeficiency Virus (HIV).
    Type: Application
    Filed: September 17, 2010
    Publication date: December 6, 2012
    Applicant: Sanofi Pasteur, Inc.
    Inventors: James T. Tartaglia, Sanjay Gurunathan, Jerome H. Kim, Donald Francis
  • Publication number: 20120308618
    Abstract: The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKL5KLK and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)13 and wherein the peptide and the oligodeoxynucleotide are present as sterile-filterable nanoparticles in the composition, thereby forming a suspension, characterized in that the mean particle size of the solid particles is less than 1 ?m.
    Type: Application
    Filed: February 21, 2011
    Publication date: December 6, 2012
    Applicant: Intercell AG
    Inventors: Benjamin Wizel, Karin Riedl, Karen Lingnau, Ursula Schlosser, Jürgen Wruss, Robert Schlegl, Michael Weber, Christoph Reinisch, Ljubomir Paucz, Christoph Klade, Jee Loon Look, Christian Ruiz, Robert Seid
  • Patent number: 8323661
    Abstract: The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives.
    Type: Grant
    Filed: August 30, 2011
    Date of Patent: December 4, 2012
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Howley, Sonja Leyrer, Paul Chaplin, Eva Felder
  • Patent number: 8323662
    Abstract: Materials and methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein are provided. More specifically, methods for generating such materials include culturing in a culture medium including kifunensine a virus packaging cell with a lentiviral vector genome including a polynucleotide encoding an exogenous antigen, a polynucleotide encoding a Sindbis E2 glycoprotein that preferentially binds dendritic cells expressing DC-SIGN, and a polynucleotide encoding a Vpx protein or a Vpr protein that retains SAMHD1-inhibiting activity, followed by isolating a pseudotyped lentiviral vector particle that preferentially binds dendritic cells expressing DC-SIGN.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: December 4, 2012
    Assignee: Immune Design Corp.
    Inventors: Christopher James Nicolai, Semih Ullah Tareen
  • Patent number: 8318419
    Abstract: The present invention provides for testing methods to determine an effective testing agent that affects the activity of the HIV Gag protein at the plasma membrane of a cell, and specifically, effecting changes in the structural conformation of at least one fatty acid of PI(4,5)P2, a member of a family of differentially phosphorylated phosphatidylinositides, wherein inhibition of the extension of such fatty acid into the MA domain of the Gag protein reduces binding of Gag to the plasma membrane, thereby inhibiting virus particle assembly and subsequent replication of the HIV virus.
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: November 27, 2012
    Assignee: University of Maryland, Baltimore County
    Inventors: Michael F. Summers, Jamil S. Saad
  • Patent number: 8309098
    Abstract: The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: November 13, 2012
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Howley, Sonja Leyrer, Paul Chaplin, Eva Felder
  • Publication number: 20120276141
    Abstract: Provided herein are small molecule CD4 mimetics effective to bind to HIV Env proteins. A CD4 mimetic of the invention, when bound to an Env protein, is effective to induce a conformational change in the Env protein such that cyptic epitopes on the Env protein are exposed. Also provided herein are related methods of identifying and using such small molecule CD4 mimetics, for example, to elicit an immune response in a subject upon administration.
    Type: Application
    Filed: June 8, 2012
    Publication date: November 1, 2012
    Inventors: Indresh K. Srivastava, Victoria Sharma, Susan W. Barnett, Jeffrey Ulmer
  • Publication number: 20120269848
    Abstract: This invention relates to cholesterol-sequestering agents and methods of using cholesterol-sequestering agents to treat or prevent infection. The compositions of the invention can be used in vitro or in vivo to decrease the load of a microorganism in a biological sample. Methods of generating an immune response against a microorganism are also included.
    Type: Application
    Filed: June 18, 2012
    Publication date: October 25, 2012
    Inventors: George A. Scheele, James E. Hildreth
  • Publication number: 20120269851
    Abstract: The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polypeptides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.
    Type: Application
    Filed: February 17, 2012
    Publication date: October 25, 2012
    Applicants: University of Stellenbosch, NOVARTIS VACCINES & DIAGNOSTICS, INC.
    Inventors: Jan zur Megede, Susan Barnett, Ying Lian, Susan Engelbrecht, Estrelita Janse van Rensburg, Thomas J. Scriba
  • Patent number: 8293465
    Abstract: The present invention relates to an antibody mimetic of carbohydrate binding module (CBM) which specifically binds to an epitope on HIV glycoprotein. The present invention also relates to a method of detecting HIV glycoprotein.
    Type: Grant
    Filed: April 6, 2010
    Date of Patent: October 23, 2012
    Assignee: National Tsing Hua University
    Inventors: Margaret Dah-Tsyr Chang, Yuan-Chuan Lee, Rong-Yuan Huang, Shu-Chuan Lin, Wei-I Chou, Shi-Hwei Liu
  • Publication number: 20120258135
    Abstract: The invention provides methods of formulating an anti-inflammatory composition for treating inflammatory conditions in a specific organ or tissue. The method involves selecting at least one pathogen that is pathogenic in the specific organ or tissue; producing an antigenic composition comprising antigenic determinants that together are specific for the pathogen; and formulating the antigenic composition for administration as an anti-inflammatory composition capable of eliciting an anti-inflammatory response in the specific organ or tissue. In embodiments of the invention the pathogen may be an endogenous pathogen, such as an endogenous bacterial pathogen. The pathogen may be an exogenous pathogen, such as a bacterial pathogen, viral pathogen, a fungal pathogen, or a helminth pathogen.
    Type: Application
    Filed: January 26, 2012
    Publication date: October 11, 2012
    Inventors: Harold David Gunn, Salim Dhanji, Brett Anthony Premack, Michael Tak Huai Chow
  • Publication number: 20120251537
    Abstract: PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist.
    Type: Application
    Filed: March 30, 2012
    Publication date: October 4, 2012
    Inventors: Rafi Ahmed, Rama Amara, Gordon Freeman, Arlene Sharpe
  • Publication number: 20120244182
    Abstract: The invention provides immunostimulatory compositions and methods of administration thereof. Also provided are methods of administering a tryptanthrin compound in an effective amount to enhance the immune response of a subject to an antigen. Also provided are methods of administering an effective amount of a tryptanthrin to stimulate the immune response in a subject for the treatment of cancer. Further provided are methods of administering a tryptanthrin compounds as an immunotherapeutic in the treatment of infectious diseases.
    Type: Application
    Filed: June 4, 2012
    Publication date: September 27, 2012
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventor: Nicholas M. VALIANTE
  • Publication number: 20120237544
    Abstract: The present invention relates to a method of coating a spore with one or more therapeutic agents. The present invention also relates to a coated spore obtained by the method of the present invention and the use of the coated spore as a vaccine.
    Type: Application
    Filed: September 21, 2010
    Publication date: September 20, 2012
    Applicant: Royal Holloway and Bedford New College
    Inventors: Simon Michael Cutting, Hong Anh Huynh
  • Patent number: 8268323
    Abstract: Stabilized forms of gp120 polypeptide, nucleic acids encoding these stabilized forms, vectors comprising these nucleic acids, and methods of using these polypeptides, nucleic acids, vectors and host cells are disclosed. Crystal structures and computer systems including atomic coordinates for stabilized forms of gp120, and gp120 with an extended V3 loop, and methods of using these structures and computer systems are also disclosed.
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: September 18, 2012
    Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Dana Farber Cancer Institute, Inc.
    Inventors: Peter Kwong, John Mascola, Gary Nabel, Richard Wyatt, Barna Dey, Ling Xu, Tongqing Zhou, Joseph Sodroski, Wen Yuan, Shi-Hua Xiang
  • Publication number: 20120225093
    Abstract: The present invention relates to compositions and methods of treating, inhibiting, or controlling HIV infection.
    Type: Application
    Filed: October 11, 2011
    Publication date: September 6, 2012
    Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
    Inventors: Michael B. Mathews, Hartmut M. Hanauske-Abel, Tsafi Pe'ery, Mainul Hoque, Paul Palumbo, Deepti Saxena, Darlene D'Alliessi-Gandolfi, Myung-Hee Park
  • Publication number: 20120225083
    Abstract: The invention is directed to polypeptides and polypeptide fragments from HIV-1 envelope (Env) proteins following the characterization of Env structures from environments where HIV isolates expose conserved neutralization-sensitive Env structures. There is provided a polypeptide being all or a fragment of an HIV-1 envelope protein from a transmission strain of HIV-1, the polypeptide having neutralization sensitive epitopes that are accessible.
    Type: Application
    Filed: September 16, 2009
    Publication date: September 6, 2012
    Applicants: THE UNIVERSITY OF MELBOURNE, THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH, NEWSOUTH INNOVATIONS PTY LIMITED
    Inventors: Damian Purcell, Robert Center, Sharmila Mohana Rama Reddy, Anthony Dominic Kelleher, David Albert Cooper, Paul Rene Gorry, Jasminka Sterjovski
  • Publication number: 20120219583
    Abstract: The invention is directed to a nucleic acid molecule encoding a HIV-1 polypeptide which comprises the nucleic acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4. The invention also provides a method of inducing an immune response against HIV-1 in a mammal.
    Type: Application
    Filed: October 15, 2010
    Publication date: August 30, 2012
    Applicants: Los Alamos National Security, LLC, The U.S. of America, as rep. by the Sec., Dept. of HHS
    Inventors: Gary J. Nabel, Zhi-Yong Yang, Wing-Pui Kong, Bette Korber
  • Publication number: 20120207784
    Abstract: Disclosed herein are isolated rubella viral vector constructs that include a rubella non-structural protein open reading frame (ORF) with an in-frame deletion, a rubella structural protein ORF, and a heterologous antigenic insert. In one example, the in-frame deletion within the rubella non-structural protein ORF is an in-frame deletion between two NotI restriction enzyme sites. In some examples, the heterologous antigenic insert is positioned within the rubella non-structural protein ORF. In other examples, the heterologous antigenic insert is positioned within the rubella structural protein ORF. Exemplary antigenic inserts include a Gag antigenic insert, a gp41 antigenic insert or a gp120 antigenic insert. Also disclosed are uses of the isolated rubella viral vector, such as to induce an immune response to HIV-1, testing sensitivity to neutralizing antibodies, or screening antiviral drugs (such as protease inhibitors).
    Type: Application
    Filed: October 15, 2010
    Publication date: August 16, 2012
    Inventors: Ira Berkower, Angelo Spadaccini
  • Publication number: 20120207765
    Abstract: A compound represented by general formula (I): a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic erythematosus, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiac/vascular disease (for example, arteriosclerosis, myocardial infarction, stenocardia, cerebral infarction, chronic arterial occlusive disease, etc.), metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.
    Type: Application
    Filed: March 8, 2012
    Publication date: August 16, 2012
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Masaya Kokubo, Hiroshi Ochiai, Yoshikazu Takaoka, Shiro Shibayama
  • Publication number: 20120207783
    Abstract: Provided herein are HIV vaccines comprising HIV polypeptide-encoding DNA adsorbed to PLG and/or HIV proteins. Also provided are methods of using these vaccines to generate immune responses in a subject.
    Type: Application
    Filed: December 22, 2011
    Publication date: August 16, 2012
    Inventors: John DONNELLY, Susan W. BARNETT, Derek O'HAGAN
  • Patent number: 8236324
    Abstract: An HIV-1 type (or subtype) O retrovirus protein, or a natural or synthetic polypeptide or peptide including at least a part of said protein, which is capable of being recognized by antibodies isolated from a serum resulting from infection by an HIV-1 type O VAU strain or an HIV-1 type (or subtype) O DUR strain.
    Type: Grant
    Filed: November 2, 2006
    Date of Patent: August 7, 2012
    Assignee: Institut Pasteur
    Inventors: Pierre Charneau, François Clavel, Andrew Borman, Caroline Quillent, Denise Guetard, Luc Montagnier, Jacqueline Donjon de Saint-Martin, Jacques Cohen
  • Publication number: 20120195852
    Abstract: Improved vaccines which include a nucleotide sequence that encodes immunomodulating protein operably linked to regulatory elements are disclosed. The improved vaccines include DNA vaccines, recombinant vaccines for delivering foreign antigen and live attenuated vaccines. Methods of immunizing individuals are disclosed. Compositions for and methods of treating individuals with autoimmune diseases are disclosed.
    Type: Application
    Filed: January 27, 2012
    Publication date: August 2, 2012
    Inventors: David B. Weiner, Jong J. Kim, Jeong-Im Sin
  • Publication number: 20120195928
    Abstract: Compositions comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with one or more of CTACK protein, TECK protein, MEC protein and functional fragments thereof and/or an isolated nucleic acid molecule that encodes a protein selected from the group consisting of: CTACK, TECK, MEC and functional fragments thereof are disclosed. Methods of inducing an immune response, including methods of inducing mucosal immune responses, in an individual against an immunogen, using such compositions are disclosed.
    Type: Application
    Filed: October 28, 2011
    Publication date: August 2, 2012
    Inventors: David B. Weiner, Michele Kutzler
  • Publication number: 20120189657
    Abstract: The present invention includes cold-adapted, acid-fast bacterium for use as a vaccine and a vaccine vector. In preferred embodiments, the cold-adapted, acid-fast bacterium is a Mycobacteria, for example, Mycobacteria shottsii.
    Type: Application
    Filed: March 30, 2012
    Publication date: July 26, 2012
    Applicant: University of Georgia Research Foundation, Inc.
    Inventors: Frederick Quinn, Candace McCombs, Russell K. Karls
  • Patent number: 8226955
    Abstract: Env-CD4 polypeptide complexes and hybrids that expose cryptic epitopes important in virus neutralization are disclosed. Method of diagnosis, treatment and prevention using the polypeptides are also provided.
    Type: Grant
    Filed: August 19, 2010
    Date of Patent: July 24, 2012
    Assignee: Novartis Vaccines & Diagnostics, Inc
    Inventors: Susan W Barnett, Indresh K Srivastava
  • Publication number: 20120183597
    Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies to HIV and to compounds and compositions suitable for use in such a method.
    Type: Application
    Filed: October 4, 2011
    Publication date: July 19, 2012
    Applicant: DUKE UNIVERSITY
    Inventors: Barton F. Haynes, S. Munir Alam, Hua-Xin Liao
  • Publication number: 20120183557
    Abstract: Hybrid molecules comprising CD4 minimal modules or mimetics that bind to HIV Env polypeptides in combination with one or more HIV Tat polypeptides are described. Also described are complexes of these hybrid molecules with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides.
    Type: Application
    Filed: March 22, 2012
    Publication date: July 19, 2012
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS. INC.
    Inventors: Susan BARNETT, Rino RAPPUOLI, Victoria A. SHARMA, Indresh K. SRIVASTAVA, Jan ZUR MEGEDE
  • Publication number: 20120177677
    Abstract: Provided are peptide vaccines including the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I-restricted epitopes and are recognized and presented by the majority of the vaccinated human population. Further provided, in particular, are anti tuberculosis vaccines. Also further provided are compositions including the vaccines as well as their use to treat or prevent infection.
    Type: Application
    Filed: July 15, 2010
    Publication date: July 12, 2012
    Applicant: VAXIL BIOTHERAPEUTICS LTD.
    Inventor: Lior Carmon
  • Publication number: 20120171244
    Abstract: Mucosal immunization using one or more antigens following parenteral administration of the same or different antigens is described.
    Type: Application
    Filed: February 4, 2012
    Publication date: July 5, 2012
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventor: Derek O'Hagan
  • Publication number: 20120171242
    Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.
    Type: Application
    Filed: January 19, 2012
    Publication date: July 5, 2012
    Applicant: VACCIBODY AS
    Inventors: Bjarne BOGEN, Agnete Brunsvik Fredriksen, Inger SANDLIE
  • Publication number: 20120171292
    Abstract: The disclosure relates to immunizing agents and devices.
    Type: Application
    Filed: January 3, 2012
    Publication date: July 5, 2012
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Michael J. Sailor, Stephen M. Hedrick, Lou Gu, Laura Ruff, Zhengtao Qin
  • Patent number: 8206720
    Abstract: Fusion proteins comprising CD4 minimal modules that bind to HIV Env polypeptides in a non-CD4 backbone are described. Also described are complexes of these fusion proteins with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.
    Type: Grant
    Filed: June 8, 2005
    Date of Patent: June 26, 2012
    Assignee: Novartis Vaccines & Diagnostics, Inc
    Inventors: Vega Masignani, Maria Scarselli, Barbara Capecchi, Victoria Sharma, Susan W. Barnett, Indresh K. Srivastava, Rino Rappuoli
  • Publication number: 20120156219
    Abstract: The compound represented by formulae (I) and (II), the salt thereof, the N-oxide thereof or the solvate thereof, or the prodrug thereof and the pharmaceutical composition comprising thereof have a CXCR4-regulating effect, and they are effective in treatment and prevention of various inflammatory disease, various allergic disease, acquired immunodeficiency syndrome infection with human immunodeficiency virus, or agents for regeneration therapy. (wherein ring A represents a nitrogen-containing heterocyclic group which may have a substituent(s); ring B represents a homocyclic group which may have a substituent(s) or a heterocyclic group which may have a substituent(s); and Y represents a hydrocarbon group which may have a substituent(s), a heterocyclic group which may have a substituent(s), an amino group which may be protected, a hydroxyl group which may be protected or a mercapto group which may be protected; T represents ring A or an amino group which may be protected.
    Type: Application
    Filed: February 22, 2012
    Publication date: June 21, 2012
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Hiromu HABASHITA, Masaya KOKUBO, Shiro SHIBAYAMA, Hideaki TADA, Tatsuya TANIHIRO
  • Publication number: 20120148621
    Abstract: The present invention is directed to a method for promoting or stimulating a cell-mediated immune response to an antigen, by administering a target antigen (such as a protein) with a transport factor that contains a fragment of a bipartite protein exotoxin, but not the corresponding protective antigen. Preferred transport factors include the protective antigen binding domain of lethal factor (LFn) from B. anthracis, consisting of amino acids 1-255, preferably a fragment of at least 80 amino acids that shows at least 80% homology to LFn, and a fragment of about 105 amino acids from the carboxy portion that does not bind PA. The target antigen can include any molecule for which it would be desirable to elicit a CMI response, including viral antigens and tumor antigens.
    Type: Application
    Filed: June 11, 2010
    Publication date: June 14, 2012
    Applicant: VACCINE TECHNOLOGIES, INCORPORATED
    Inventors: Yichen Lu, Nicholas Kuchner, Amie Strong, Zhenhui Xu
  • Patent number: 8198088
    Abstract: The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: June 12, 2012
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Howley, Sonja Leyrer, Paul Chaplin, Eva Felder
  • Patent number: 8197821
    Abstract: The present invention relates to protein-protein interactions involved in AIDS. More specifically, the present invention relates to complexes of polypeptides or polynucleotides encoding the polypeptides, fragments of the polypeptides, antibodies to the complexes, Selected Interacting Domains (SID®) which are identified due to the protein-protein interactions, methods for screening drugs for agents which modulate the interaction of proteins and pharmaceutical compositions that are capable of modulating the protein-protein interactions.
    Type: Grant
    Filed: February 25, 2008
    Date of Patent: June 12, 2012
    Assignee: Laboratoire Biodim
    Inventors: Pierre Legrain, Jean-Christophe Rain, Richard Benarous, Stéphane Emiliani, Clarissa Berlioz-torrent, Guillaume Blot
  • Patent number: 8197819
    Abstract: Provided herein are small molecule CD4 mimetics effective to bind to HIV Env proteins. A CD4 mimetic of the invention, when bound to an Env protein, is effective to induce a conformational change in the Env protein such that cyptic epitopes on the Env protein are exposed. Also provided herein are related methods of identifying and using such small molecule CD4 mimetics, for example, to elicit an immune response in a subject upon administration.
    Type: Grant
    Filed: June 8, 2005
    Date of Patent: June 12, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Indresh K. Srivastava, Victoria Sharma, Susan W. Barnett, Jeffrey Ulmer
  • Patent number: 8197822
    Abstract: The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives.
    Type: Grant
    Filed: August 15, 2011
    Date of Patent: June 12, 2012
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Howley, Sonja Leyrer, Paul Chaplin, Eva Felder
  • Publication number: 20120141526
    Abstract: The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides methods and compositions for the use of nanoemulsion compounds as mucosal adjuvants to induce immunity against environmental pathogens. Accordingly, in some embodiments, the present invention provides nanoemulsion vaccines comprising a nanoemulsion and an inactivated pathogen or protein derived from the pathogen. The present invention thus provides improved vaccines against a variety of environmental and human-released pathogens.
    Type: Application
    Filed: October 30, 2007
    Publication date: June 7, 2012
    Applicant: The Regents of the University of Michigan
    Inventors: James R. Baker, Anna Bielinska, Andrzej Myc
  • Publication number: 20120141465
    Abstract: The invention relates to compositions and methods that employ OX40 (CD134), a TNFR superfamily protein, agonists. The invention includes among other things administering an OX40 agonist alone or in combination with a viral antigen, or live or attenuated virus, to treat a viral infection, or for vaccination or immunization.
    Type: Application
    Filed: October 4, 2007
    Publication date: June 7, 2012
    Applicant: La Jolla Institute for Allergy and Immunology
    Inventors: MICHAEL CROFT, Shahram Salek-Ardakani, Magdalini Moutaftsi, Alessandro Sette, Carl F. Ware